Eculizumab in secondary atypical haemolytic uraemic syndrome

Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. Methods. We identified 29 patients with so-called secon...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavero, Teresa, Rabasco, Cristina, López, Antía, Román, Elena, Ávila, Ana, Sevillano, Ángel, Huerta, Ana, Rojas-Rivera, Jorge, Fuentes, Carolina, Blasco, Miquel, Jarque, Ana, García, Alba, Mendizabal, Santiago, Gavela, Eva, Macía, Manuel, Quintana, Luis F., María Romera, Ana, Borrego, Josefa, Arjona, Emi, Espinosa, Mario, Portolés, José, Gracia-Iguacel, Carolina, González-Parra, Emilio, Aljama, Pedro, Morales, Enrique, Cao, Mercedes, Rodríguez de Córdoba, Santiago, Praga, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410989/
https://www.ncbi.nlm.nih.gov/pubmed/28339660
http://dx.doi.org/10.1093/ndt/gfw453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410989/
https://www.ncbi.nlm.nih.gov/pubmed/28339660
http://dx.doi.org/10.1093/ndt/gfw453

Ejemplares similares